Rezultati pretraživanja
  1. 30. sij

    Prof. Ludwig ist ein großartiger Wissenschaftler und Kollaborator. Seit Jahren arbeiten wir erfolgreich mit ihm zusammen, um gegen zu entwickeln.

  2. 30. sij
    Odgovor korisniku/ci

    Prof. Ludwig ist ein großartiger Wissenschaftler und Kollaborator. Seit Jahren arbeiten wir erfolgreich mit ihm zusammen, um gegen zu entwickeln

  3. 29. sij

    The world is under virus attack, but German scientists are already on the move. spoke with Prof. Dr. Ludwig, developer of ’ host-targeting candidate, , about pandemic threats like , SARS, MERS and .

  4. 14. sij

    We look forward to telling you more about , our host-targeting approach to treat , at the RESI conference, where 500+ early stage investors gather every year. Dr. Rainer Lichtenberger will present Atriva during the track 4, 8:00 am.

  5. 13. sij

    Learn more about ’s host-targeting therapy candidate against , hanta and further severe respiratory viral infections at the company presentation of our CEO, Dr. Lichtenberger, today at . Join us at 11:30, Franciscan D.

  6. 15. pro 2019.

    reports the weekly status of Germany’s incidence. As every year, the maximum is expected in February. ’s is developing to reduce the occurrence of and flu-like-illness by inhibiting the virus’ replication machinery independently of the strain.

  7. 20. stu 2019.

    ’s strategy and product candidate “may revolutionize treatment of and other severe respiratory viral infections” and be “a quantum leap in respiratory therapies”. Learn more in the article by

  8. 8. stu 2019.

    announces the successful conclusion of the Ph. I trial for in . Dr. Lichtenberger, CEO: “An important milestone towards a novel flu drug against this public health danger and its threat of a new

  9. 4. stu 2019.

    On Nov 11 , EU's largest life science partnering conference, starts in . Our CEO Dr. Lichtenberger is happy to discuss our lead product against , and other severe respiratory infections. Use to set up a meeting!

  10. 1. stu 2019.

    Let’s go by spreading awareness - today is ! Atriva commits to with our first-in-class host-targeting MEK inhibitor . We address the need for a novel, broadly active, resistance-avoiding therapy and for a prolonged treatment window.

  11. 20. lis 2019.

    Atriva Theraputics is now also on Twitter! We can’t wait to tell you more about our lead product , a clinical- stage, first-in-class host-targeting agent that inhibits viral replication in and other respiratory infections. Stay tuned!

  12. 28. lip 2019.
  13. 27. lip 2019.
    Prikaži ovu nit

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.